ADAR1 Capital Management’s Vir Biotechnology VIR Stock Holding History

ADAR1 Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25M	Sell	2,456,677 -288,037	-10%	-$2.74M	1.15%	16
2026 Q1	$24.6M	Buy	+2,744,714	New	+$21.9M	1.45%	14
2025 Q3	–	Sell	-250,000	Closed	-$1.26M	–	265
2025 Q2	$1.26M	Hold	250,000	–	–	0.19%	73
2025 Q1	$1.62M	Buy	250,000 +185,933	+290%	+$1.65M	0.3%	64
2024 Q4	$470K	Sell	64,067 -255,118	-80%	-$2.01M	0.09%	113
2024 Q3	$2.39M	Buy	319,185 +209,185	+190%	+$1.82M	0.39%	45
2024 Q2	$979K	Buy	+110,000	New	+$1.05M	0.18%	66

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ADAR1 Capital Management's VIR Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Vir Biotechnology (VIR) stake by 10% in Q2 2026, selling an estimated $2.74M and leaving 2,456,677 shares worth $25M. The position accounts for 1.15% of the portfolio, ranked #16.

ADAR1 Capital Management first reported a position in VIR in Q2 2024 and has held it in 7 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

ADAR1 Capital Management held 2,456,677 shares of Vir Biotechnology worth $25M as of Q2 2026.
ADAR1 Capital Management sold 288,037 Vir Biotechnology shares in Q2 2026, an estimated $2.74M.
Vir Biotechnology made up 1.15% of ADAR1 Capital Management's portfolio in Q2 2026, its #16 holding.
ADAR1 Capital Management first reported a position in Vir Biotechnology in Q2 2024 and has held it in 7 quarters since.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.